Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

NCT05418556 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

3944

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: aspirin

Sponsor

Asan Medical Center